DB:H9O1

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

HumanOptics AG develops, manufactures, and sells intraocular implantable solutions.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has HumanOptics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: H9O1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.4%

H9O1

-9.6%

DE Medical Equipment

-1.4%

DE Market


1 Year Return

-23.6%

H9O1

22.3%

DE Medical Equipment

8.0%

DE Market

Return vs Industry: H9O1 underperformed the German Medical Equipment industry which returned 21.6% over the past year.

Return vs Market: H9O1 underperformed the German Market which returned 8.1% over the past year.


Shareholder returns

H9O1IndustryMarket
7 Day-5.4%-9.6%-1.4%
30 Day-9.9%-0.7%-1.2%
90 Day-19.7%-1.4%12.6%
1 Year-23.6%-23.6%23.9%22.3%10.4%8.0%
3 Year17.8%17.8%132.4%127.5%4.7%-3.7%
5 Year107.6%107.6%238.3%225.0%15.9%0.3%

Price Volatility Vs. Market

How volatile is HumanOptics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is HumanOptics undervalued compared to its fair value and its price relative to the market?

14.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate H9O1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate H9O1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: H9O1 is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.

PE vs Market: H9O1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate H9O1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: H9O1 is overvalued based on its PB Ratio (14.8x) compared to the DE Medical Equipment industry average (4.8x).


Next Steps

Future Growth

How is HumanOptics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HumanOptics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has HumanOptics performed over the past 5 years?

-52.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: H9O1 is currently unprofitable.

Growing Profit Margin: H9O1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: H9O1 is unprofitable, and losses have increased over the past 5 years at a rate of 52.5% per year.

Accelerating Growth: Unable to compare H9O1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: H9O1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.6%).


Return on Equity

High ROE: H9O1 has a negative Return on Equity (-77.17%), as it is currently unprofitable.


Next Steps

Financial Health

How is HumanOptics's financial position?


Financial Position Analysis

Short Term Liabilities: H9O1's short term assets (€6.0M) exceed its short term liabilities (€4.3M).

Long Term Liabilities: H9O1's short term assets (€6.0M) exceed its long term liabilities (€3.7M).


Debt to Equity History and Analysis

Debt Level: H9O1's debt to equity ratio (292.5%) is considered high.

Reducing Debt: H9O1's debt to equity ratio has increased from 113.7% to 292.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if H9O1 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if H9O1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is HumanOptics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate H9O1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate H9O1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if H9O1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if H9O1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of H9O1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average board tenure


CEO

Diana Bachmann

0.58

Tenure

Ms. Diana Bachmann serves as Vice President of Finance & Administration at HumanOptics AG and also serves as its Member of Management Board since May 01, 2020. She has been the Chief Executive Officer and ...


Board Members

NamePositionTenureCompensationOwnership
Yeying Huang
Member of Supervisory Boardno datano datano data
Yijing Xiao
Member of Supervisory Board0.58yrno datano data
Lijuan Li
Chairman of Supervisory Board0.58yrno datano data
Jan Martens
Vice Chairman of Supervisory Board0.58yrno datano data
Xuxing Xu
Member of Supervisory Board0.58yrno datano data

0.6yrs

Average Tenure

Experienced Board: H9O1's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.9%.


Top Shareholders

Company Information

HumanOptics AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: HumanOptics AG
  • Ticker: H9O1
  • Exchange: DB
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €33.304m
  • Shares outstanding: 3.49m
  • Website: https://www.humanoptics.com

Number of Employees


Location

  • HumanOptics AG
  • Spardorfer Str. 150
  • Erlangen
  • Bavaria
  • 91054
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
H9O1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2006

Biography

HumanOptics AG develops, manufactures, and sells intraocular implantable solutions. The company offers artificial intraocular lenses. It also provides CUSTOMFLEX ARTIFICIALIRIS, an iris prosthesis, which i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/05 20:49
End of Day Share Price2020/08/05 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.